Jazz Pharmaceuticals The pharmaceutical giant announced last week that its flagship cannabinoid treatment, Epidyolex, failed to pass its Phase
As reported by Cannabis Health Avata Biosciences is developing solid dose cannabinoid medicines for epilepsy and other neurological disorders, with
Germany’s passage of CanG continues to drive up stock prices Yesterday, the President of Bundesrat, Manuela Schwesig, signed Germany’s landmark
IM Cannabis IM Cannabis has become the latest major Israeli cannabis company to announce potential plans to depart the industry
Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth
Jazz Pharmaceuticals Epidiolex (Epidyolex in the EU and UK), Jazz Pharmaceuticals’ market leading cannabis-based medication, has received authorisation to
Japan, one of the world’s strictest and most hostile countries in regard to cannabis, recently took a major step towards
Big pharma has so far been cautious of diving headfirst into the cannabis industry, despite the growing body of evidence
German Stocks Spike on Passage of Draft Law Synbiotic SE (SBX) Yesterday, the German federal cabinet officially passed the draft
Pharmaceutical cannabis industry sales are expected to grow by over 20% over the next four years, from $1.14b to $1.37b
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
